Repligen Corp. says it has joined the University of Michigan in a lawsuit alleging that a newly approved rheumatoid arthritis drug from Bristol-Myers Squibb Corp. violates a patent covering therapeutic uses of a molecule that helps regulate the body's immune response. Repligen said it holds exclusive rights to the patent, which grew out of research by the university and the U.S. Navy.
January 10, 2006 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Repligen Corp. said Friday it has joined the University of Michigan in a lawsuit alleging a newly approved rheumatoid arthritis drug from Bristol-Myers Squibb Corp. violates a patent.
New York City-based Bristol-Myers Squibb won federal approval last month to market a drug under the trade name Orencia as a treatment for the chronic disease, which affects more than 2 million people in the United States. Analysts have estimated the drug could eventually reach $1 billion in annual sales.
Presented by BigVoodoo
Join the industry's top owners, investors, developers, brokers & financiers at THE MULTIFAMILY EVENT OF THE YEAR!
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Lower Manhattan firm seeks a premises liability litigator (i.e., depositions, SJ motions, and/or trials) with at least 3-6 years of experien...
At NJM, a top-rated insurance company, we are seeking an Attorney on our Workers Compensation legal team with between 3 and 5 years of expe...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
